Pelvic inflammatory disease secondary prevention

Pelvic inflammatory disease Microchapters
Home
Patient Information
Overview
Historical Perspective
Pathophysiology
Causes
Differentiating Pelvic Inflammatory Disease from other Diseases
Epidemiology and Demographics
Risk Factors
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Pelvic inflammatory disease secondary prevention On the Web
Most recent articles
cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Pelvic inflammatory disease secondary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Pelvic inflammatory disease secondary prevention
CDC on Pelvic inflammatory disease secondary prevention
Pelvic inflammatory disease secondary prevention in the news
Blogs on Pelvic inflammatory disease secondary prevention
to Hospitals Treating Pelvic inflammatory disease
Risk calculators and risk factors for Pelvic inflammatory disease secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Seyedmahdi Pahlavani, M.D. [2]

Overview

Sexual partner evaluation and treatment are the mainstays of secondary prevention for PID.

Secondary prevention

• Sexual partners of woman who diagnosed with PID in last 60 days of onset of her symptoms must be evaluated and treated for possible chlamydia or gonorrhea infection.
• Infected women should avoid sexual contact until they and their partners have completed the evaluation and treatment.